CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial
Authors
Arthur Kavanaugh
Bruce Crawford
+22 more
Daniel E Furst
David Curtis
E D Keystone
Elliott Kopp
Eric Ruderman
Grant W Cannon
Herbert B Lindsley
Indra Fernando
Jacques Caldwell
Joan Bathon
Joel Kremer
John Cush
Jonathan Waltuck
Joseph Markenson
Karen Simpson
Mark Genovese
MD J Kremer
Michael Luggen
Michael Weisman
Patricia Coleman
Seth Kantor
Vibeke Strand
Publication date
11 April 2020
Publisher
Abstract
P e r s o n a l n o n -c o m m e r c i a l u s e o n l y . T h e J o u r n a l o f R h e u m a t o l o g y . C o p y r i g h t © 2 0 0 4 . A l l r i g h t s r e s e r v e d Conclusion. Response to therapy was maintained to 48 weeks of treatment in patients who continued to receive LEF and MTX during the extension. Importantly, ACR20 response rates after 24 weeks of LEF therapy were similar between patients switched from PLA to LEF without loading dose, and those who received a loading does of LEF (100 mg/day × 2 days) at randomization. Fewer adverse events were reported in patients switched to LEF without a loading dose. (J Rheumatol 2004;31:1521-31
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
CiteSeerX
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:CiteSeerX.psu:10.1.1.1054....
Last time updated on 07/12/2020